Suppr超能文献

根治性低剂量率近距离放射治疗中剂量率变化的补偿:一项随机临床试验的放射生物学分析

Compensation for changes in dose-rate in radical low-dose-rate brachytherapy: a radiobiological analysis of a randomised clinical trial.

作者信息

Roberts Stephen A, Hendry Jolyon H, Swindell Richard, Wilkinson John M, Hunter Robin D

机构信息

Biostatistics Group, School of Epidemiology and Health Sciences, University of Manchester, Manchester M13 9PT, UK.

出版信息

Radiother Oncol. 2004 Jan;70(1):63-74. doi: 10.1016/j.radonc.2003.11.010.

Abstract

BACKGROUND AND PURPOSE

This study reanalysed the results of the Cs-137 low-dose-rate brachytherapy trials for stage I and II cervix carcinoma at the Christie Hospital, Manchester, UK, in order to quantify the clinical outcome as a function of dose, and to extract radiobiological parameter values by modelling the data for local control and morbidity.

PATIENTS AND METHODS

Kaplan-Meier survival curves and Cox regression analyses were used to analyse the time to event data. Linear-quadratic (LQ) analysis was also used in a mixture model, incorporating a half-time for repair, a time factor, and a heterogeneity function between patients. Full 5-year follow-up data were available for 339 patients receiving Cs-137 doses between 60 and 75 Gy delivered at 1.4-1.8 Gy/h, and 178 patients receiving a Ra-226 dose of 75 Gy at 0.5 Gy/h, using two insertions 7-10 days apart.

RESULTS

With the increased dose-rate, a dose reduction between 20 and 25% was required to achieve a similar morbidity rate. This reduction had a detrimental effect on tumour control, by about 15% points. Unexpectedly, this loss in local control did not lead to a decrease in cancer-specific survival. For both tumour control and complications a high alpha/beta and short half-time for repair best fitted the data, suggesting that consequential late reactions may be responsible for much of the bowel and urinary morbidity after these short treatments. The variability in response between patients was greater (CV 40%) for morbidity than for tumour control (CV 17%), probably reflecting the greater variation in dose at the target tissue. There was no significant dependence on overall treatment time detected over the 7-10-day range of these treatments.

CONCLUSIONS

The therapeutic ratio was somewhat less for the higher dose-rate, in agreement with radiobiological expectations, although cancer-specific survival was inexplicably unchanged. The LQ-parameter analysis suggests that high alpha/beta ratios and/or short repair half-times are applicable for both tumour and normal tissue responses in these treatments.

摘要

背景与目的

本研究重新分析了英国曼彻斯特克里斯蒂医院针对Ⅰ期和Ⅱ期宫颈癌进行的铯 - 137低剂量率近距离放射治疗试验结果,以便将临床结局量化为剂量的函数,并通过对局部控制和并发症数据进行建模来提取放射生物学参数值。

患者与方法

采用Kaplan - Meier生存曲线和Cox回归分析来分析事件发生时间数据。线性 - 二次(LQ)分析也用于混合模型,该模型纳入了修复半衰期、时间因子以及患者之间的异质性函数。对于339例接受1.4 - 1.8Gy/h剂量为60至75Gy的铯 - 137治疗的患者以及178例接受间隔7 - 10天分两次插入、剂量率为0.5Gy/h的镭 - 226剂量75Gy治疗的患者,可获得完整的5年随访数据。

结果

随着剂量率增加,需要降低20%至25%的剂量才能达到相似的并发症发生率。这种剂量降低对肿瘤控制有不利影响,降低幅度约为15个百分点。出乎意料的是,局部控制的这种损失并未导致癌症特异性生存率下降。对于肿瘤控制和并发症而言,高α/β值和短修复半衰期最能拟合数据,这表明在这些短疗程治疗后,后续的迟发反应可能是导致大部分肠道和泌尿系统并发症的原因。患者之间并发症反应的变异性(CV 40%)大于肿瘤控制反应的变异性(CV 17%),这可能反映了靶组织剂量的更大变异性。在这些治疗的7 - 10天范围内,未检测到对总治疗时间的显著依赖性。

结论

尽管癌症特异性生存率 inexplicably不变,但较高剂量率的治疗比在某种程度上较低,这与放射生物学预期一致。LQ参数分析表明,高α/β比值和/或短修复半衰期适用于这些治疗中肿瘤和正常组织的反应。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验